1-20 of 593 Search Results for

pharmaceutical

Follow your search
Access your saved searches in your account

Would you like to receive an alert when new items match your search?
×Close Modal
Sort by
Journal Article
Journal of Health Politics, Policy and Law (1 October 2006) 31 (5): 1015–1019.
Published: 01 October 2006
.... Christopher Scott Harrison. The Politics of the International Pricing of Prescription Drugs. Westport, CT: Praeger, 2004. 224 pp. $65.95 cloth. Richard Henry Parrish II. Defining Drugs: How Government Became the Arbiter of Pharmaceutical Fact. New Brunswick, NJ: Transaction Books, 2003. 163 pp. $29.95...
Journal Article
Journal of Health Politics, Policy and Law (1 October 2012) 37 (5): 779–814.
Published: 01 October 2012
..., Australia, and the United Kingdom — specifically, why Canada alone failed to adopt nationwide, public pharmaceutical insurance. It demonstrates that the pace of change has significant implications for the scope of policy development. It provides new mechanisms to explain why incremental reforms stall based...
Journal Article
Journal of Health Politics, Policy and Law (1 June 2013) 38 (3): 505–544.
Published: 01 June 2013
...Denis G. Arnold; James L. Oakley As the pharmaceutical industry lobbies European regulators to permit direct-to-consumer advertising (DTCA) of prescription drugs in the European Union, we found that five leading companies violated industry-developed and -promulgated standards for ethical...
Journal Article
Journal of Health Politics, Policy and Law (1 August 2013) 38 (4): 735–755.
Published: 01 August 2013
...Bhaven N. Sampat; Tahir Amin The 1995 Trade Related Intellectual Property Rights (TRIPS) agreement required developing countries to grant product patents in pharmaceuticals. Developing countries have since explored various measures to ameliorate potential negative effects of the new laws on public...
Journal Article
Journal of Health Politics, Policy and Law (1 June 2014) 39 (3): 691–705.
Published: 01 June 2014
... political and regulatory environment, this report explores pharmaceutical pricing options for Russia that balance greater access to medicines with achieving government plans of boosting local pharmaceutical production. To match innovative medicine prices with their health benefits, in the long run, we...
Journal Article
Journal of Health Politics, Policy and Law (1 April 2016) 41 (2): 157–179.
Published: 01 April 2016
...Denis G. Arnold; Jennifer L. Troyer Abstract The pharmaceutical industry has been criticized for developing and aggressively marketing drugs that do not provide significant health benefits relative to existing drugs but retain the benefits of patent protection. Critics argue that drug marketing...
Journal Article
Journal of Health Politics, Policy and Law (1 December 2009) 34 (6): 931–977.
Published: 01 December 2009
...John Abraham Coinciding with sixty years of the U.K. National Health Service (NHS), this article reviews the neglected area of the governance of the pharmaceutical industry and the NHS. It traces the relationships between the pharmaceutical industry, the state, and the NHS from the creation of the...
Journal Article
Journal of Health Politics, Policy and Law (1 August 1992) 17 (4): 847–868.
Published: 01 August 1992
...Louis H. Orzack; Kenneth I. Kaitin; Louis Lasagna The European Community (EC) plans to create a single market for pharmaceutical medicines, but the drug industry is closely linked to cultural and societal values concerning health; to the national regulatory agencies responsible for the evaluation...
Journal Article
Journal of Health Politics, Policy and Law (1 February 2003) 28 (1): 109–132.
Published: 01 February 2003
...Ramón Castellblanch A comparison of the Vermont and Maine cases of attempting to control pharmaceutical prices in the year 2000 shows that the Maine legislators were more successful in challenging pharmaceutical industry political power. This comparison shows that challenging the industry was...
Journal Article
Journal of Health Politics, Policy and Law (1 June 2003) 28 (2-3): 473–508.
Published: 01 June 2003
...” is usually applied to the individual or consumer level,this article develops the concept of organized voice and illustrates how it has exhibited leadership in the controversial relations between the biotech and pharmaceutical industries and society as a whole. The essay concludes by urging more...
Journal Article
Journal of Health Politics, Policy and Law (1 June 2016) 41 (3): 423–450.
Published: 01 June 2016
...Elize Massard da Fonseca; Francisco Inácio Bastos Abstract The protection of pharmaceutical intellectual property (IP) rights is one of the most controversial debates in contemporary public health as countries have to balance incentives for drug development with the necessity of providing life...
Journal Article
Journal of Health Politics, Policy and Law (1 August 2003) 28 (4): 615–658.
Published: 01 August 2003
...Mary E. Wiktorowicz Although industrialized nations regulate pharmaceuticals to ensure their safety and efficacy, they balance these concerns with those related to the timeliness of the approval process and the burdens involved in meeting regulatory criteria. The United States, Canada, Britain, and...
Journal Article
Journal of Health Politics, Policy and Law (1 February 2018) 43 (1): 5–18.
Published: 01 February 2018
... drugs will require close coordination among manufacturers, payers, and regulators. Copyright © 2018 by Duke University Press 2018 Medicaid best-price rule pharmaceutical pricing value-based payment outcome-based pricing Even in today's polarized political landscape, a consensus has emerged...
Journal Article
Journal of Health Politics, Policy and Law (1 April 1998) 23 (2): 265–290.
Published: 01 April 1998
...Mae Thamer; Niall Brennan; Rafael Semansky Six countries—Canada, France, Japan, Sweden, the United Kingdom, and the United States—were studied to compare public policies affecting the development and marketing of pharmaceuticals for rare diseases (i.e., orphan drugs). Information was obtained from...
Journal Article
Journal of Health Politics, Policy and Law (1 December 2009) 34 (6): 979–1010.
Published: 01 December 2009
...Sandra Adamini; Hans Maarse; Esther Versluis; Donald W. Light After lengthening the duration of patents to twenty years in 1984, the pharmaceutical industry has turned to data exclusivity as a major vehicle for extending market protection, even after patents expire. Such protections give companies...
Journal Article
Journal of Health Politics, Policy and Law (1 April 1979) 4 (2): 155–175.
Published: 01 April 1979
... control prices of pharmaceuticals, prior to enactment of some form of national health insurance, if successful, will call forth pharmaceutical industry strategies which could negate program benefits. Copyright © 1979 by the Dept. of Health Administration, Duke University 1979 The authors wish to express...
Journal Article
Journal of Health Politics, Policy and Law (1 June 2013) 38 (3): 545–571.
Published: 01 June 2013
...Joel Lexchin; Mary Wiktorowicz; Kathy Moscou; Laura Eggertson The Canadian constitution divides the responsibility for pharmaceuticals between the federal and provincial governments. While the provincial governments are responsible for establishing public formularies, the majority of the safety and...
Journal Article
Journal of Health Politics, Policy and Law (1 June 2013) 38 (3): 573–597.
Published: 01 June 2013
...Félix Lobo; Roger Feldman This article studies how well International Nonproprietary Names (INNs), the “generic” names for pharmaceuticals, address the problems of imperfect information. Left in private hands, the identification of medicines leads to confusion and errors. Developed in the 1950s by...
Journal Article
Journal of Health Politics, Policy and Law (1 December 2005) 30 (6): 1003–1026.
Published: 01 December 2005
...Soonman Kwon; Michael R. Reich Korea recently introduced three major health care reforms: in financing (1999), pharmaceuticals (2000), and provider payment (2001). In these three reforms, new government policies merged more than 350 health insurance societies into a single payer, separated drug...
Journal Article
Journal of Health Politics, Policy and Law (1 April 2008) 33 (2): 225–247.
Published: 01 April 2008
... variables, among which is budget impact. Budget impact refers to the total costs that drug reimbursement and use entail with respect to one part of the health care system, pharmaceutical care, or to the entire health care system, taking into account the possible reallocation of resources across budgets or...